Maravai Lifesciences (MRVI) acquired intellectual property and relevant assets from Molecular Assemblies for an undisclosed price.

The acquisition will expand customer development of next-generation mRNA and CRISPR nucleic acid-based therapies, Maravai said Tuesday in a statement.